Charlotte Enghave Fruergaard, PhD

PRO Devices A/S
CEO & Co-founder
Charlotte Enghave Fruergaard, Ph.D., is CEO and Co-founder of PRO Devices A/S. Our vision is to make everyday life easier for staff in microbial laboratories. We add value to the laboratories by optimising manual workflow of weary routines, using automated resistance measurements, which is a time-consuming routine task. We have developed equipment that reads the size of all inhibition-zones on disc diffusion tests, at the same time the individual antibiotic discs are identified, and documentation and traceability are ensured with photo-documentation.

Previously she was more than 26 years at NNE working in various positions from Principal Consultant in Compliance Consulting, Director of Finished Products, and Manager of Sales & Marketing and before that responsible for conceptual designs of new pharmaceutical facilities. Enghave Fruergaard has over 26 years of experience with pharmaceutical projects. Enghave Fruergaard holds an MSc in mechanical engineering and a PhD in measuring technique. She has international experience from an EU founded project where she was stationed at Physicalische Technische Bundesanstalt in Germany. During this project, she also gained the PhD degree within metrology.

Enghave Fruergaard has been a Member of ISPE since 1995 and was Chairman of the International Board of Directors in 2012/2013. She is co-founder of ISPE Nordic Affiliate in 2000 and was Chairman of the Nordic Affiliate in 2006-2007. She has been the conference leader of numerous ISPE Barrier Isolation/Aseptic Conferences in Europe since 1999. She is a member of the steering committees for ISPE Sterile Products Processing Community of Practice, ISPE Women in Pharma and the 2021 ISPE Annual Meeting & Expo Program Committee.

Related Articles

The Next Horizon for Therapy Innovations
iSpeak Blog
The Next Horizon for Therapy Innovations

The industry is continuously evolving to meet new requirements. Many of these requirements include adhering to global regulatory harmonization, improving supply chain robustness, minimizing drug shortages, reducing the complexity of managing product life cycles, and reducing the environmental impact of pharmaceutical processes. At the

Agility & Innovations in Process Development and Manufacturing
iSpeak Blog
Agility & Innovations in Process Development and Manufacturing

The needs of patients must always be at the forefront of what we do.

Many of our colleagues are taking on the challenge of rethinking the old ways. They are collaborating with each other and the regulatory agencies to take effective steps to remain at the forefront of regulatory science and innovation. Why? In order to ensure the continued delivery of effective medicines.